Announcement PDF Market Announcement 30 October 2024 Amplia Therapeutics Limited (ASX: ATX) – Trading Halt Description The securities of Amplia Therapeutics Limited (‘ATX’) will be placed in trading halt at the request of ATX, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Friday, 1 November 2024. Issued by ASX Compliance 30 October 2024 ASX Limited #10818441v1 Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au ABN 16 165 160 841 30 October 2024 AMPLIA THERAPEUTICS LIMITED (ASX: ATX) - REQUEST FOR TRADING HALT Pursuant to Listing Rule 17.1, Amplia Therapeutics Limited ACN 165 160 841 (the Company or Amplia) requests that ASX grant an immediate trading halt for all of Amplia’s securities. In accordance with Listing Rule 17.1, the Company advises that: • the trading halt is requested pending an announcement regarding a capital raising, to be undertaken by way of a share placement and pro rata, accelerated, non-renounceable entitlement offer (Offer); • the trading halt is required to enable the Offer to be undertaken in an orderly manner; • Amplia requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the Offer and the commencement of trading on Friday, 1 November 2024; and • Amplia is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt. This trading halt request was authorised for release by the Board of Amplia Therapeutics Limited. - End Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com